Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets. In the historic dot.com year 2000, he trained as a CEFA analyst in Frankfurt and has since then accompanied over 20 IPOs in Germany.
Until 2018, he held various positions at banks as an asset manager, capital market and macro expert as well as fundamental equity analyst. He is passionate about the energy, commodity and technology markets as well as the tactical and strategic asset allocation of liquid investment products. As an expert speaker at investment committee meetings of funds as well as at customer events, he can still describe the course of the 1987 crash, one of the major buying opportunities of the last 33 years on the stock market.
Today, he knows that the profit in shares is not necessarily the result of buying cheaply, but above all of avoiding mistakes and recognizing in good time when markets are ready to let air out. After all, in addition to basic fundamental analysis, investing in stocks is above all a phenomenon of global liquidity and this must be monitored regularly.
Commented by André Will-Laudien
Commented by André Will-Laudien on August 26th, 2025 | 07:20 CEST
Big moves! Buying frenzy at Novo Nordisk and PanGenomic Health, Valneva left behind
Things are moving again in the biotech sector! While Novo Nordisk appears to have finally found its footing after three profit warnings, PanGenomic Health continues its upward trend. Since launching its new business model in May, the stock has staged a phenomenal rally of over 1,000%. Meanwhile, Valneva faces a major setback as the US Food and Drug Administration (FDA) has halted approval of the chikungunya vaccine Ixchiq due to severe side effects. This comes as a shock to investors, who are now waiting for the Company to provide further explanations. The stock market has reacted with a sharp drop in the share price. How can investors benefit from the current situation?
Read
Commented by André Will-Laudien on August 25th, 2025 | 07:00 CEST
100% with NATO contracts from the air! Airbus, Globex Mining, Boeing, and Lufthansa
The craziness continues! NATO member states have agreed on new planning targets for armaments and capabilities and, according to Secretary General Mark Rutte, have increased the requirements for air and missile defense by about 30%. Rutte stated: "We need more resources, troops, and capabilities to be prepared for any threat." German Chancellor Friedrich Merz emphasised that Germany would provide all the necessary resources to expand the Bundeswehr into the strongest conventional army in Europe. According to experts, large-scale defense projects, particularly in the aerospace sector, will require enormous investments and far-reaching acquisitions. Across Europe, around EUR 300 billion is expected to be invested in air forces by 2030. Investors should now set the course to benefit from the flood of orders in the aerospace sector.
Read
Commented by André Will-Laudien on August 21st, 2025 | 07:20 CEST
Defense sell-off – New doublers are emerging with thyssenkrupp, Almonty, and Heidelberger Druck
What defense speculators always feared as a looming threat is now happening within just one week: Peace negotiations between Russia and Ukraine! Even though nothing concrete has happened yet, the sentiment is clear: If only half of the numerous geopolitical conflicts calm down or even disappear entirely, the pressure to rearm will ease, and potential orders, which were already reflected extensively in share prices, could be reduced or canceled altogether. Public budgets resemble a pressure cooker at 120 degrees, so any relief is welcome. It will be interesting to see how far defense stocks might fall, especially after rising by up to 2000% in the case of Rheinmetall. Almonty remains interesting because, even with reduced defense demand, critical metals remain the bottleneck of Western industries. It is worth taking a closer look.
Read
Commented by André Will-Laudien on August 21st, 2025 | 07:15 CEST
High-tech correction! A brief pause, then the party continues at Palantir, Deutsche Telekom, MiMedia, and SAP
Oops – there it is. The first correction at Palantir was somewhat severe. But after a 1000% increase in 24 months – who cares? The blockbuster themes of artificial intelligence, cloud computing, and big data continue to dominate the stock market, leading to significant daily price gains. Investors seem to view the capital markets as an almost one-way success story in which valuations play hardly any role. Europe is increasingly taking the lead, with the EURO STOXX 50 rising by around 20% since the tariff dip in April. Despite apparent risks, many investors are sticking to the bull market, although the S&P 500's high Shiller P/E ratio of over 38 is sending out a clear warning signal. Deutsche Telekom is generating excitement with the announcement of another innovation push in the form of its first AI-based smartphone. The coming weeks therefore offer exciting opportunities for investors who, despite the warning signs, are betting on the continued momentum of the market. Where to invest?
Read
Commented by André Will-Laudien on August 21st, 2025 | 07:05 CEST
The AI revolution is turning biotech into a gold mine! BioNTech, Eli Lilly, NetraMark Holdings, and Pfizer know how!
Artificial intelligence (AI) is becoming increasingly important in drug research and is revolutionizing the development of new active ingredients. Machine learning and neural networks enable large amounts of data to be analyzed and potential drugs to be identified more quickly. AI also plays a central role in the planning and execution of clinical trials by recognizing data patterns, identifying suitable patients, and thus increasing the chances of success. The market for AI in drug development is growing rapidly. Experts estimate it will reach several billion US dollars by 2025, with projected annual growth of over 40%. Where are the opportunities and risks for agile investors?
Read
Commented by André Will-Laudien on August 20th, 2025 | 07:05 CEST
Rethinking energy! Siemens Energy, First Hydrogen, VW, and BYD for the winning portfolio
For a long time, it seemed that nuclear energy was disappearing from the global energy mix, but now there are clear signs of a change of course. The US, in particular, is pushing for a restart. The government has adopted an ambitious plan to quadruple nuclear power capacity. The focus is on small modular reactors (SMRs) - compact reactors that can be used in decentralized locations, are considered efficient and safe, and can also be built more quickly than conventional large-scale power plants. In addition to their role in domestic energy supply, SMRs are considered an important export product for allied countries looking to reduce their dependence on fossil fuels. At the same time, they offer the possibility of being flexibly combined with renewable energy sources, such as supplementing solar and wind farms to ensure base load capability. E-mobility also depends on a secure power supply. Which companies are attracting the most investor interest?
Read
Commented by André Will-Laudien on August 19th, 2025 | 07:10 CEST
Ukraine hangs in the balance, and demand for defense remains high! Rheinmetall, Hensoldt, Antimony Resources, and DroneShield in focus
The latest geopolitical tensions and the Trump-Putin summit in Alaska highlight how fragile global supply chains currently are due to high levels of uncertainty—especially for European industry, which is suffering from energy shortages and trade blockades. This situation is reflected in the capital markets, where interest rates are trending upward and risk premiums are increasing. Nevertheless, new record highs are being recorded almost daily. Under pressure from rising commodity prices, Western industrial companies in particular are facing the challenge of realigning their procurement strategies in order to survive in an increasingly fragmented global trade environment. This opens up opportunities for investors who respond flexibly and resiliently to these changes. So which investments should investors focus on to successfully navigate their portfolios through this turbulent phase of global upheaval?
Read
Commented by André Will-Laudien on August 18th, 2025 | 07:05 CEST
Hydrogen versus nuclear power – 300% with Plug Power and dynaCERT, caution advised with Oklo and NuScale
Fuel cells have long been seen as a beacon of hope in propulsion technology, though they have only gained limited traction in the automotive sector. While batteries dominate the mass market, fuel cells score points primarily in heavy-duty and long-distance transport due to their range and short refueling times, as well as in stationary systems. Plug Power is working on infrastructure projects, while dynaCERT is making existing drives more efficient with hydrogen systems, thus serving as a bridge to the next era. At the same time, small modular reactors (SMRs) from suppliers like Oklo and NuScale are gaining in importance as they promise a stable, low-carbon energy supply for industry and hydrogen production. This opens up opportunities for investors in two future markets: sustainable mobility and scalable energy solutions – both enjoying political tailwinds and high growth potential. How should investors proceed with their portfolios?
Read
Commented by André Will-Laudien on August 13th, 2025 | 07:15 CEST
Attention, Takeovers: Things are heating up! Bayer, Eli Lilly, Vidac Pharma, and Formycon in focus
Volatility is king! Great for speculators, often difficult for long-term investors. Biotech stocks are extremely sensitive to study and approval news, especially in cancer research. Vidac Pharma is developing drugs that are designed to target tumor cells and cause them to die – risky, but with great potential. Despite its restructuring, Bayer is strengthening its oncology pipeline, especially in niche indications. Eli Lilly is benefiting from the boom in modern immunotherapies and, thanks to its strong financial position, can support long development phases. Formycon is considering entering the oncology market to broaden its base. The sector offers opportunities and surprising takeovers, but requires a high tolerance for risk.
Read
Commented by André Will-Laudien on August 12th, 2025 | 07:25 CEST
Crash in the defense sector? Geopolitical conflicts drive up metal prices! Rheinmetall, Sranan Gold, Hensoldt, and RENK
Strategic metals are a decisive factor in the economic strength and military power of entire nations. International hotspots like the Middle East, Ukraine and, most recently, Africa are exacerbating shortages, as long-established trade routes can collapse abruptly. The high concentration of production in a few countries increases the vulnerability of supply chains to political intervention. Export bans, sanctions or targeted supply restrictions by China or Russia can quickly lead to critical supply shortages. In this environment, precious metals like gold, which is currently trading at historic price levels, are becoming even more important for investors, not least against the backdrop of record-high government debt worldwide. Those who act flexibly can benefit from this commodity dynamic. The long-running favorites of recent months in the defense sector now appear to be consolidating. Where to put the money?
Read